Want to track LDZA and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Earnings results expected in 88 days
Summary
LDZA trading today higher at €4.7, an increase of 1.29% from yesterday's close, completing a monthly increase of 2.17% or €0.1. Over the past 12 months, LDZA stock lost -43.71%.
LDZA is not paying dividends to its shareholders.
The last earnings report, released on 10 hours ago, exceeded the consensus estimates by 0%. On average, the company has surpassed earnings expectations by 0%, based on the last three reports. The next scheduled earnings report is due on Mar 03, 2026.
The stock of the company had never split.
The company's stock is traded on 8 different exchanges and in various currencies, with the primary listing on XFRA (EUR).
LDZA Chart
Aspen Pharmacare Holdings Limited (LDZA) FAQ
What is the stock price today?
The current price is €4.70.
On which exchange is it traded?
Aspen Pharmacare Holdings Limited is listed on XFRA.
What is its stock symbol?
The ticker symbol is LDZA.
Does it pay dividends? What is the current yield?
Yes, It pays dividends and the current yield is 0.48%.
What is its market cap?
As of today, no market cap data is available.
When is the next earnings date?
The next earnings report will release on Mar 03, 2026.
Has Aspen Pharmacare Holdings Limited ever had a stock split?
No, there has never been a stock split.
Aspen Pharmacare Holdings Limited Profile
| - Industry | - Sector | Mr. Stephen Bradley Saad BCom, CA(SA) CEO | XDUS Exchange | ZAE000066692 ISIN |
| ZA Country | 8,867 Employees | 18 Sep 2024 Last Dividend | 19 Apr 2016 Last Split | - IPO Date |
Overview
Aspen Pharmacare Holdings Limited, a pioneering force in the pharmaceutical industry, orchestrates the manufacture and global distribution of specialty and branded pharmaceutical products through its extensive network of subsidiaries. It distinctly segments its operations into Commercial Pharmaceuticals and Manufacturing. Originally established in 1850 and currently with its headquarters nestled in Durban, South Africa, Aspen Pharmacare has grown to play a pivotal role in the global pharmaceutical landscape, addressing a wide range of healthcare needs.
Products and Services
Aspen Pharmacare’s product portfolio spans across various therapeutic areas, showcasing a diversified range of pharmaceutical solutions:
- Diprivan, Emla, Fraxiparine, Marcaine, Ultiva, and Xylocaine: These brand names represent Aspen’s foray into anesthetics, including general, local, and regional anesthesia options, offering solutions for surgical pain management and procedural sedation.
- Circadin, Eltroxin, Foxair, Imuran, Maltofer, Mybulen, and Ovestin: These brands cater to a variety of medical conditions. Circadin is utilized as a sleeping aid, addressing insomnias and sleep disorders. Eltroxin serves as a thyroid hormone replacement therapy, essential for managing hypothyroidism. Foxair offers respiratory relief for conditions like asthma through its airway dilating properties, while Imuran, an immunosuppressant, is crucial for patients undergoing organ transplants or suffering from autoimmune diseases. Maltofer provides an iron supplement solution, combatting iron deficiency anemia. Mybulen, an analgesic anti-inflammatory, assists in managing pain and inflammation, whereas Ovestin offers hormone replacement therapy, specifically tailored for menopausal symptoms.
- Active Pharmaceutical Ingredients (APIs) and Finished Dose Form Products: Beyond its bespoke brand offerings, Aspen is also instrumental in the production and distribution of active pharmaceutical ingredients, crucial for the pharmaceutical manufacturing process. It extends its expertise to finished dose form products, ensuring quality pharmaceuticals are accessible globally.
Contact Information
Address: Aspen Place
Phone: 27 31 580 8600
Website: https://www.aspenpharma.com
2025 © Marketlog. All Rights Reserved.
